ASCO Annual Meeting: Breast Cancer

Articles

Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy

Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.

Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.

Ultralow Risk 70-Gene Signature May Indicate Survival Outcomes in Early-Stage Breast Cancer 

Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients. 

Neoadjuvant Durvalumab Plus Chemotherapy Effective in Early-Stage TNBC

With a de-escalation strategy for administration of trastuzumab and pertuzumab in the neoadjuvant setting, patients with HER2-positive, hormone receptor–negative breast cancer experienced high rates of response and survival.

De-escalated Neoadjuvant Trastuzumab/Pertuzumab Induced Sufficient Responses in HER2+/HR– Breast Cancer

Ribociclib (Kisqali) plus fulvestrant (Faslodex) maintained significantly improved overall survival (OS) rates after nearly 5 years of follow-up compared to fulvestrant alone in postmenopausal patients who had hormone receptor (HR)-postivie, HER2-negative advanced breast cancer. 

Ribociclib Plus Fulvestrant Continued to Improve OS in Advanced, HR+ Breast Cancer, Regardless of Setting

Venetoclax plus fulvestrant did not result in better outcomes compared to fulvestrant alone in previously treated patients who had locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer.

Venetoclax Plus Fulvestrant Did Not Improve Outcomes Compared to Fulvestrant Alone in ER+/HER2- Breast Cancer 

Palbociclib plus fulvestrant maintained a clinically meaningful overall survival improvement compared to placebo plus fulvestrant after a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

Palbociclib Plus Fulvestrant Combo Maintains Long-Term OS Benefit

Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer. 

Efficacy Elicited From Olaparib in BRCA1/2+, HER2– Early Breast Cancer Persists 1 Year After Standard Treatment

The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer.

ASCO Annual Meeting: Breast Cancer | Conference